+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pembrolizumab"

From
Urothelial Cancer Drugs Market Report 2025 - Product Thumbnail Image

Urothelial Cancer Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
Ewing Sarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Ewing Sarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 115 Pages
  • Global
From
T-cell Malignancies - Pipeline Insight, 2025 - Product Thumbnail Image

T-cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
Malignant Pleural Mesothelioma- Pipeline Insight, 2025 - Product Thumbnail Image

Malignant Pleural Mesothelioma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
4-1BB Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

4-1BB Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Leiomyosarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Leiomyosarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Merkel Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Merkel Cell Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Loading Indicator

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers. Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated. Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more